Abstract
Thirty-seven patients with multiple myeloma (stage II and III, 65% increased β2-microglobulin level) were prospectively treated with a median of 3.7 VAD courses (range 2–8) followed by cyclophosphamide (6 g/m2) in conjunction with G-CSF (5 μg/kg filgrastrim (n = 14), or 3.5 μg/kg lenograstrim (n = 22)), and peripheral stem cell (PSC) isolation. After regeneration this was followed by one EDAP course and high-dose melphalan (HDM, 200 mg/m2) in combination with re-infusion of PSC. Adequate stem cell mobilization was obtained with both G-CSF regimens. A median of 41 × 106 CD34+ cells/kg (range 4.5–161) was collected in a median of 1.6 leukapheresis procedures following filgrastrim (n = 14) and 24 × 106 CD34+ cells/kg (range 2.3–80) in a median of 1.7 leukapheresis procedures following lenograstrim (n = 22) which indicated no significant difference (P = 0.24) between both G-CSF regimens. A rapid hematological recovery was obtained after HDM with reinfusion of a median of 9.3 × 106 CD34+ cells/kg. After the total courses the overall response was 84% with a complete remission rate of 30%. Currently the median overall survival is 44.0 months (95% CI 38.9–49.1) with a median follow-up of 33 months (range 3–51) and a median event-free survival of 29.0 months (95% CI 25.3–32.7) (n = 33). Post transplantation a high incidence of oligloclonal serum immunoglobulins (Igs) was observed. In 73% of the patients new oligoclonal or monoclonal serum bands were noticed 3 months post transplantation. IgG-λ and IgG-κ bands predominated. In 48% of the cases the oligoclonal Igs disappeared after a median follow-up of 22 months (range 8–36), whereas in 52% of the cases the oligoclonal Igs persisted with a median follow-up of 31 months (range 21–45), which did not correlate with a significant difference in overall, and event-free survival between both subgroups. Bone Marrow Transplantation (2000) 25 , 723–728.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Greipp PR . Advances in the diagnosis and management of myeloma Semin Haematol 1992 29: 24–45
Alexanian R, Dimopoulos M . The treatment of multiplemyeloma New Engl J Med 1994 330: 484–490
Cunningham D, Paz-Ares L, Gore ME et al. High-dose melphalan for multiple myeloma: long-term follow-up data J Clin Oncol 1994 12: 764–769
Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596
Harousseau JL, Attal M, Marit G et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on Autologous Transplantation in Multiple Myeloma Blood 1995 85: 3077–3086
Demuynck H, Delforge M, Verhoef G et al. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF Br J Haematol 1995 90: 384–393
Zent CS, Wilson CS, Tricot G et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation Blood 1998 91: 3518–3523
Durie BGM, Salmon SE . A clinical staging system for multiple myeloma Cancer 1975 36: 42–52
Pascali E, Pezzoli A, Chiardini A . Immunofixation: application to the identification of difficult monoclonal components Clin Chem 1982 28: 1404–1405
Vellenga E, de Wolf JThM, Beentjes JAM et al. Divergent effects of interleukin-4 on the granulocyte colony-stimulating factor and IL-3 supported myeloid colony formation from normal and leukemic bone marrow cells Blood 1990 75: 633–637
Barlogie B, Velasquez WS, Alexian R, Cabanillas F . Etoposide, dexamethasone, cytarabine and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma J Clin Oncol 1989 7: 1514–1517
Jagannath J, Barlogie B Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors Blood 1990 76: 1860–1866
Attal M, Huguet F, Schlaifer D et al. Intensive combined therapy for previously untreated aggressive myeloma Blood 1992 79: 1130–1136
Corradini P, Voena C, Astolfi M et al. High dose sequential chemotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting Blood 1995 85: 1596–1602
Vellenga E, Van Putten WLJ, Boogaerts MA et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant 1999 23: 1279–1282
Gerritsen EJA, van Tol MJD, Lankester AC et al. Immunoglobulin levels and monoclonal gammopathies in children after bone marrow transplantation Blood 1993 82: 3493–3502
Hammarstrom L, Edvard Smith CI . Frequent occurrence of monoclonal gammopathies with an imbalanced light-chain ratio following bone marrow transplantation Transplantation 1987 3: 447–450
Mitus AJ, Stein R, Rappeport JM et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation Blood 1989 74: 2764–2768
Fischer AM, Simon F, Le Deist F et al. Prospective study of the occurrence of monoclonal gammopathies following bone marrow transplantation in young children Transplantation 1990 49: 731–735
Hovenga S, Wolf de JThM, Klip H, Vellenga E . Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature Bone Marrow Transplant 1997 20: 901–904
Guikema JEJ, Vellenga E, Veeneman JM et al. Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation Br J Haematol 1999 104: 748–754
Acknowledgements
We are grateful to Ruth Egger and the haemopheresis team of the Blood Bank for the continuous support of this study and CA Stegeman for statistical assistance. This study was supported by the Jan Kornelis de Cock Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hovenga, S., de Wolf, J., Guikema, J. et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant 25, 723–728 (2000). https://doi.org/10.1038/sj.bmt.1702194
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702194
Keywords
This article is cited by
-
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Journal of Experimental & Clinical Cancer Research (2022)
-
Comparison of SPE, IFE, and FLC in Monitoring Patients with Multiple Myeloma After Autologous Stem Cell Transplantation
Cell Biochemistry and Biophysics (2015)
-
Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma
Annals of Hematology (2014)
-
Molecular analysis of immunoglobulin genes reveals frequent clonal relatedness in double monoclonal gammopathies
Blood Cancer Journal (2013)
-
Prognostic value of unrelated atypical serum immunofixation patterns during Multiple Myeloma therapy
Journal of Hematology & Oncology (2012)